• Logic-gated Switch-DARPin design enables potent, selective cytotoxicity against cells co-expressing tumor-associated antigens (TAAs) previously considered undruggable for T cell engagers
• Favorable safety profile, with new data indicating healthy tissues expressing either TAA remain intact
• Attractive therapeutic window underlines MP0632’s readiness for IND-enabling studies in solid tumors co-expressing MSLN and EpCAM

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.